Chimeric Bait Receptors for Combatting Airborne Viral Infections Can Be Delivered Intranasally
Hemogenyx Pharma Plc (LON:HEMO) FDA Consents to Phase I Trials of HEMO-CAR-T
Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has been informed by the U.S. Federal Food and Drug Administration (“FDA”) that it has lifted the clinical hold on the Investigational
Hemogenyx Pharma Plc (LON:HEMO) Approval and Issuance of U.S. Conditioning Patent
HemoGenyx Pharmaceuticals (LON: HEMO) announced the approval of a crucial patent application by the United States Patent and Trademark Office, safeguarding its innovative CDX antibody technology.
Hemogenyx Pharma Plc (LON:HEMO) Submission of Complete Response to Clinical Hold
Submission of Complete Response to Clinical Hold for HEMO-CAR-T IND
Hemogenyx Pharma Plc (LON:HEMO) CBR Expanded to Treatment of Cancer
Chimeric Bait Receptor-programmed macrophages show promise for the treatment of Non-Hodgkin Lymphoma
Hemogenyx Pharma Plc (AIM:HEMO) Strategic Investment from Prevail Partners, LLC
Hemogenyx Pharmaceuticals Announces Strategic Investment from Prevail Partners, LLC
Hemogenyx Pharma Plc (AIM:HEMO) HEMO-CAR-T 3rd Process Qualification Run Completed
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its third Process Qualification (“PQ”) run of
Hemogenyx Pharma Plc (LON:HEMO) Single CBR Can Treat Multiple Viruses
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor (“CBR”) platform technology, designed to program immune cells to
Hemogenyx Pharma Plc Update With The Appointment of Medical Director
One of America’s Top Bone Marrow Transplant and Oncology Doctors Joins Hemogenyx Pharmaceuticals as Medical Director
Hemogenyx Pharma Plc (AIM:HEMO) CBR Update
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has achieved proof of concept (“POC”) for its
Hemogenyx Pharma Plc (AIM: HEMO) HEMO-CAR-T pre-IND Meeting Request
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration (“FDA”) that the proposed pre-Investigational
Hemogenyx Pharma Plc (HEMO.L) Hemo-CAR-T partnership with WuXi ATU
Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programme